New drug ASP1002 enters early human testing for Hard-to-Treat cancers

NCT ID NCT05719558

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug, ASP1002, in adults with advanced solid tumors that have high levels of a protein called claudin 4. The main goals are to check the drug's safety, find the best dose, and see how well people tolerate it. Participants receive the drug through an IV infusion weekly, every other week, or every 3 weeks for up to 2 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer neoplasm Neoplasm Metastasis non-small cell lung carcinoma ovarian carcinoma prostate adenocarcinoma triple-negative breast carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut
RECRUITING

Plainville, Connecticut, 06062, United States
HealthPartners Cancer Research Center
RECRUITING

Saint Paul, Minnesota, 55101, United States
Henry Ford Hospital
RECRUITING

Detroit, Michigan, 48202, United States
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Mary Crowley Cancer Research Center
RECRUITING

Dallas, Texas, 75251, United States
NEXT Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Norton Cancer Institute
RECRUITING

Louisville, Kentucky, 40202, United States
Prisma Health-Upstate Cancer Institute
COMPLETED

Greenville, South Carolina, 29605, United States
SCRI Oncology Partners
COMPLETED

Nashville, Tennessee, 37203, United States
Swedish Cancer Institute
RECRUITING

Edmonds, Washington, 21632, United States
University Hospitals of Cleveland
RECRUITING

Cleveland, Ohio, 44106, United States
University of Florida
RECRUITING

Gainesville, Florida, 32610, United States
University of Iowa Hospitals
RECRUITING

Iowa City, Iowa, 52242, United States
University of Texas Southwestern
COMPLETED

Dallas, Texas, 75235, United States
Yale University Cancer Center
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.